E
7.05
0.08 (1.15%)
| Previous Close | 6.97 |
| Open | 6.97 |
| Volume | 227,318 |
| Avg. Volume (3M) | 246,181 |
| Market Cap | 154,117,232 |
| Price / Sales | 3.20 |
| Price / Book | 10.31 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 |
| Profit Margin | -27.34% |
| Operating Margin (TTM) | -21.71% |
| Diluted EPS (TTM) | -0.840 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 367.92% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -14.91 M |
| Levered Free Cash Flow (TTM) | -10.11 M |
| Return on Assets (TTM) | -19.21% |
| Return on Equity (TTM) | -117.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Exagen Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 19.82% |
| % Held by Institutions | 45.44% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (Keybanc, 141.14%) | Buy |
| Median | 12.00 (70.21%) | |
| Low | 11.00 (Canaccord Genuity, 56.03%) | Buy |
| Average | 13.33 (89.08%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 8.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 30 Jul 2025 | 11.00 (56.03%) | Buy | 8.63 |
| Keybanc | 30 Jul 2025 | 17.00 (141.13%) | Buy | 8.63 |
| Craig-Hallum | 23 Jul 2025 | 12.00 (70.21%) | Buy | 7.32 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Aug 2025 | Announcement | Exagen Inc. to Participate in Third Quarter Investor Conferences |
| 29 Jul 2025 | Announcement | Exagen Inc. Reports Strong Q2 2025 Results |
| 17 Jul 2025 | Announcement | Exagen Inc. Appoints Chas McKhann to Board of Directors |
| 15 Jul 2025 | Announcement | Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 |
| 23 Jun 2025 | Announcement | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |